DSM Chinese investment
This article was originally published in The Tan Sheet
Nutritional and drug ingredient manufacturer Royal DSM agrees to acquire a 10 percent stake in North China Pharmaceutical Group Corporation Ltd. and to establish a joint venture to manufacture vitamin C products. The Netherlands-based DSM says March 19 it will have a 30 percent stake in the vitamin C joint venture, plus 51 percent ownership of separate partnerships with the Hebei Province-based Chinese firm to develop active and intermediate pharmaceutical ingredients for anti-infective drugs. DSM's total cash investment will amount to approximately $110 million in the agreements the firms expect to start implementing in the second half of 2009
You may also be interested in...
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.